Product Pathways - NF-kB Signaling
IRAK Isoform Antibody Sampler Kit #4769
|Kit Includes||Quantity||Applications||Reactivity||MW (kDa)||Isotype|
|IRAK1 (D51G7) XP® Rabbit mAb #4504||40 µl||W IP IF-IC||H M Mk||78, 105||Rabbit IgG|
|IRAK2 Antibody #4367||40 µl||W IF-IC||H M R Mk||62||Rabbit|
|IRAK-M Antibody #4369||40 µl||W IF-IC||H Mk||68||Rabbit|
|IRAK4 Antibody #4363||40 µl||W IP||H M R Mk||55||Rabbit|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||Goat|
Reactivity Key: H=Human M=Mouse R=Rat Mk=Monkey
Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Specificity / Sensitivity
Each antibody in the IRAK Isoform Antibody Sampler Kit detects endogenous levels of its indicated target. Cross-reactivity has not been detected with other family members at endogenous levels.
Western blot analysis of extracts from THP-1 (human), RAW 264.7 (mouse), and H-4-II-E (rat) cell lines, using IRAK4 Antibody #4363.
Western blot analysis of extracts from Jurkat, Raji and K562 cell lines, using IRAK2 Antibody #4367.
Western blot analysis of extracts from HL-60, Raji and K562 cell lines, using IRAK-M Antibody #4369.
The IRAK Isoform Antibody Sampler Kit provides an economical means to examine total protein levels of the four Interleukin-1 Receptor Associated Kinase family members: IRAK1, IRAK2, IRAK3/IRAK-M, and IRAK4.
Source / Purification
Antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy-terminus of murine IRAK1, human IRAK2, human IRAK-M, and surrounding Lys41 of human IRAK4.
Interleukin-1 (IL-1) receptor-associated kinase (IRAK) is a serine/threonine-specific kinase that can be coprecipitated in an IL-1-inducible manner with the IL-1 receptor (1). The mammalian family of IRAK molecules contains four members (IRAK1, IRAK2, IRAK3/IRAK-M, and IRAK4). The binding of IL-1 to IL-1 receptor type I (IL-1RI) initiates the formation of a complex that includes IL-1RI, AcP, MyD88, and IRAKs (2). IRAK undergoes autophosphorylation shortly after IL-1 stimulation. The subsequent events involve IRAK dissociation from the IL-1RI complex, its ubiquitination, and its association with two membrane-bound proteins: TAB2 and TRAF6. The resulting IRAK-TRAF6-TAB2 complex is then released into the cytoplasm where it activates protein kinase cascades, including TAK1, IKKs, and the stress-activated kinases (3).
Upon IL-1R/TLR (Toll-Like Receptor) ligation, IRAK1 and IRAK4 are rapidly recruited to the receptor by the adaptor MyD88 (4). IRAK1 is phosphorylated by IRAK4 at Thr209 and Thr387 (5), followed by sequential autohyperphosphorylation in various domains. Unlike IRAK1 and IRAK4, IRAK2 and IRAK-M do not have significant kinase activity although they can still activate NF-κB when overexpressed (6,7). Antisense oligonucleotide depletion of IRAK2 can inhibit IL-1 mediated NF-κB activation (8). Expression of IRAK-M is more restricted compared to other family members with highest levels of expression occurring in monocytes/macrophages (6). Studies from IRAK-M knockout mice suggest that it may play a role as a negative regulator of TLR signaling and innate immune responses by preventing the dissociation of IRAK1 and IRAK4 from MyD88 and the subsequent formation of its complex with TRAF6 (9).
- Dinarello, C.A. (1996) Blood 87, 2095-147.
- Takaesu, G. et al. (2001) Mol Cell Biol 21, 2475-84.
- Janssens, S. and Beyaert, R. (2003) Mol Cell 11, 293-302.
- Gottipati, S. et al. (2008) Cell Signal 20, 269-76.
- Kollewe, C. et al. (2004) J Biol Chem 279, 5227-36.
- Wesche, H. et al. (1999) J Biol Chem 274, 19403-10.
- Muzio, M. et al. (1997) Science 278, 1612-5.
- Guo, F. et al. (1999) Inflammation 23, 535-43.
- Kobayashi, K. et al. (2002) Cell 110, 191-202.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 3699 MyD88 Antibody
- 4748 Tollip Antibody
- 3744 TAB2 Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
For Research Use Only. Not For Use In Diagnostic Procedures.